A bronchiectasis inflammatory endotype characterized by elevated blood eosinophils (≥300 cells/μL) or sputum eosinophils (≥3%), associated with type 2 (Th2) inflammation, elevated fractional exhaled nitric oxide (FeNO), and IL-5/IL-13 signaling. This phenotype affects approximately 20% of patients with bronchiectasis and may be responsive to inhaled corticosteroids and biologic agents targeting Th2 pathways. The disease or phenotype is Experimental Factor Ontology id EFO_0920036 (eosinophilic bronchiectasis). Also known as: eosinophilic bronchiectasis endotype.